Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-label, Multicentre Study to Provide Access to Guanfacine Hydrochloride Extended-release for European Subjects With Attention-deficit/Hyperactivity Disorder (ADHD) Who Participated in Study SPD503-315 or SPD503-316

NCT01500694 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT01500694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01500694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-label, Multicentre Study to Provide Access to Guanfacine Hydrochloride Extended-release for European Subjects With Attention-deficit/Hyperactivity Disorder (ADHD) Who Participated in Study SPD503-315 or SPD503-316
Lead sponsor
Shire
Phase
Phase 3
Overall status
Completed
Start date
March 20, 2012
Completion date
September 15, 2015
Enrollment
215 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder (adhd)